NCT02804373View on ClinicalTrials.gov

Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 31, 2019

Study Completion Date

June 18, 2019

Conditions
Prader-Willi Syndrome
Interventions
DRUG

Oxytocin (OXT) continuous

Administration of 24 IU of oxytocin daily during 28 days

DRUG

Placebo

Placebo daily during 28 days

DRUG

Placebo continuous

Placebo administration the following 2 days after each OXT administration, during 28 days.

DRUG

Oxytocin

Administration of 24 IU of oxytocin every 3 days during 28 days.

Trial Locations (1)

31059

Centre de référence Prader-Willi - Hôpital Purpan, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT02804373 - Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter